Drug intelligence / Profile preview

SOA-201

Development stage: Unknown
Lead developer: Shine-On Biomedical
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

SOA-201 is a trispecific antibody drug candidate developed by Shine-On BioMedical. It is currently in the discovery phase and is being investigated for the treatment of neoplasms, specifically triple negative breast cancer, as well as other skin and musculoskeletal diseases. As a trispecific antibody, SOA-201 is designed to simultaneously target three different antigens or epitopes, potentially enhancing its therapeutic efficacy against complex cancers such as triple negative breast cancer. Detailed information about its specific targets or mechanisms of action has not been disclosed publicly[1].

Beyond the preview

Go deeper on SOA-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOA-201.

Explore the full profile